Spasticity is a common disability in children with cerebral palsy. Pharmacological and non-pharmacological treatments, including physical therapy, occupational therapy, orthotics, rhizotomy, and orthopedic surgery, all play important roles in the management of spasticity. The purpose of this article is to provide an overview of available medications for treatment of spasticity in children with cerebral palsy. Common medications include benzodiazepines, dantrolene sodium, baclofen, tizanidine, botulinum toxins, phenol, alcohol and intrathecal baclofen. In general, oral medications and intrathecal baclofen are used for treating generalized spasticity, whilst chemodenervation agents (botulinum toxins, phenol, and alcohol) are used to treat loc...
Cerebral palsy is the most common cause of severe physical disability in childhood. Spasticity is a ...
The physical properties, mechanism of action, and clinical evidence supporting the use of botulinum ...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...
Spasticity is a common disability in children with cerebral palsy. Pharmacological and non-pharmacol...
Spasticity is a common problem in children with neurologic impairment, particularly in those with ce...
The management of the child or adult with spasticity associated with cerebral palsy may include a nu...
INTRODUCTION: Cerebral palsy is the most common cause of physical disability in children. Spasticity...
Cerebral palsy has an incidence of about 1-2 per 1000 live births, and in spite of the progress of n...
Cerebral palsy (CP) affects around every one in 500 children born. It isn’t a particular illness or ...
Introduction: Cerebral palsy (CP) is a group of disorders that affect muscle movement, tone and coor...
Cerebral palsy in children is a syndrome of disorders resulting from damage to the central nervous s...
The objective of this study was to assess the efficacy of botulinum toxin for upper limb spasticity ...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not botulinum toxin...
CP is the most common cause of chronic disability in childhood occurring in 2-2.5/1000 births. It is...
The objective Of this Study was to compare the effectiveness of baclofen versus tizanidine as adjuva...
Cerebral palsy is the most common cause of severe physical disability in childhood. Spasticity is a ...
The physical properties, mechanism of action, and clinical evidence supporting the use of botulinum ...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...
Spasticity is a common disability in children with cerebral palsy. Pharmacological and non-pharmacol...
Spasticity is a common problem in children with neurologic impairment, particularly in those with ce...
The management of the child or adult with spasticity associated with cerebral palsy may include a nu...
INTRODUCTION: Cerebral palsy is the most common cause of physical disability in children. Spasticity...
Cerebral palsy has an incidence of about 1-2 per 1000 live births, and in spite of the progress of n...
Cerebral palsy (CP) affects around every one in 500 children born. It isn’t a particular illness or ...
Introduction: Cerebral palsy (CP) is a group of disorders that affect muscle movement, tone and coor...
Cerebral palsy in children is a syndrome of disorders resulting from damage to the central nervous s...
The objective of this study was to assess the efficacy of botulinum toxin for upper limb spasticity ...
OBJECTIVE: The objective of this selective EBM review is to determine whether or not botulinum toxin...
CP is the most common cause of chronic disability in childhood occurring in 2-2.5/1000 births. It is...
The objective Of this Study was to compare the effectiveness of baclofen versus tizanidine as adjuva...
Cerebral palsy is the most common cause of severe physical disability in childhood. Spasticity is a ...
The physical properties, mechanism of action, and clinical evidence supporting the use of botulinum ...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...